Please select the option that best describes you:

In patients with metastatic hormone receptor-positive, HER2-low breast cancer, how many and which lines of therapy would you recommend prior to using trastuzumab deruxtecan?  

Are there any circumstances where use of T-DXd would supercede the use of CDK4/6 inhibitors or other non-chemotherapeutic options (PIK3CA etc?)



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Mary Bird Perkins Cancer Centers
I would likely offer verzenio prior to Enhertu if ...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more